Skip to main content
Livermore
Livermore
ZHEN

Rosalind Advisors, Inc.

SEC CIK
0001622627
Latest filing
Aug 14, 2026

The latest 13F from Rosalind Advisors, Inc. covers Q2 2026 (filed Aug 14, 2026): 29 long positions worth $266.2M. The top 10 holdings make up 74.9% of the portfolio, and the largest is Delcath Systems, Inc. (DCTH) at 15.6%. Livermore has 12 filings on Form 13F from this institution, going back to Q4 2023.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
3
Est. +$4.49M
Added
7
Est. +$17.7M
Reduced
11
Est. −$19.5M
Sold out
6
Est. −$18.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. DCTHDelcath Systems, Inc.
    15.6%$41.6MHistory
  2. FENCFennec Pharmaceuticals Inc.
    12.9%$34.3MHistory
  3. XERSXeris Biopharma Holdings, Inc.
    8.7%$23.0MHistory
  4. SVRASavara Inc
    7.4%$19.6MHistory
  5. VSTMVerastem, Inc.
    5.7%$15.2MHistory

Share of portfolio

Top 5 holdings and the other 24 positions, by share of portfolio value

  1. DCTH15.6%
  2. FENC12.9%
  3. XERS8.7%
  4. SVRA7.4%
  5. VSTM5.7%
  6. Other 24 positions49.8%

Biggest buys

New and added positions, by estimated amount bought

  1. VSTMVerastem, Inc.
    +$7.06MAddedHistory
  2. FENCFennec Pharmaceuticals Inc.
    +$3.01MAddedHistory
  3. HELPCybin Inc.
    +$2.81MAddedHistory
  4. ABVXAbivax S.A.
    +$2.78MNewHistory
  5. TLPHTalphera, Inc.
    +$1.87MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. FENCFennec Pharmaceuticals Inc.
    +5.54 pp7.3% → 12.9%History
  2. HELPCybin Inc.
    +1.85 pp3.0% → 4.9%History
  3. VSTMVerastem, Inc.
    +1.08 pp4.6% → 5.7%History
  4. ABVXAbivax S.A.
    +1.04 pp0.0% → 1.0%History
  5. TLPHTalphera, Inc.
    +0.97 pp1.0% → 2.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CGONCG Oncology, Inc.
    −$6.77MSold outHistory
  2. PCVXVaxcyte, Inc.
    −$5.23MReducedHistory
  3. VRDNViridian Therapeutics, Inc.
    −$4.90MSold outHistory
  4. CLDXCelldex Therapeutics, Inc.
    −$4.84MReducedHistory
  5. XERSXeris Biopharma Holdings, Inc.
    −$2.56MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CGONCG Oncology, Inc.
    −2.77 pp2.8% → 0.0%History
  2. PCVXVaxcyte, Inc.
    −2.54 pp6.9% → 4.4%History
  3. VRDNViridian Therapeutics, Inc.
    −2.01 pp2.0% → 0.0%History
  4. CLDXCelldex Therapeutics, Inc.
    −1.49 pp4.3% → 2.8%History
  5. DFTXDefinium Therapeutics, Inc.
    −0.97 pp1.0% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$266.2M
+$22.2M (+9.1%) vs. prior quarter
Positions
29
−3 vs. prior quarter
Top 10 concentration
74.9%
Top 10 as share of value
Turnover
8.7%
Q2 2026, one quarter
Average holding period
7.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2023), so positions held before then are understated.

13F filings by quarter

11 quarters, going back to Q4 2023. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $275.4M (Q3 2025)

Q4 2023: $119.5MQ1 2024: $106.9MQ2 2024: $126.5MQ3 2024: $150.7MQ4 2024: $185.7MQ1 2025: $205.2MQ2 2025: $206.6MQ3 2025: $275.4MQ4 2025: $260.9MQ1 2026: $244.1MQ2 2026: $266.2M
Q4 2023Q2 2026
13F filings of Rosalind Advisors, Inc. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202629$266.2MDCTHFENCXERSvs. Q1 2026SEC
Q1 2026May 14, 202632$244.1MDCTHXERSFENCvs. Q4 2025SEC
Q4 2025Feb 12, 202629$260.9MDCTHSVRAFENCvs. Q3 2025SEC
Q3 2025Nov 13, 202529$275.4MDCTHCYTKFENCvs. Q2 2025SEC
Q2 2025Aug 14, 202529$206.6MDCTHFENCCYTKvs. Q1 2025SEC
Q1 2025May 14, 202531$205.2MDCTHVSTMXERSvs. Q4 2024SEC
Q4 2024Feb 14, 2025Amended28$185.7MDCTHMYOMDWDvs. Q3 2024SEC
Q3 2024Oct 30, 202429$150.7MDCTHMYOCRMDvs. Q2 2024SEC
Q2 2024Jul 12, 202435$126.5MDCTHMYOMDWDvs. Q1 2024SEC
Q1 2024Apr 25, 202431$106.9MMYOLYRAMDWDvs. Q4 2023SEC
Q4 2023Feb 14, 202427$119.5MLYRAMYOATXS–SEC

13D and 13G filings

Companies where Rosalind Advisors, Inc. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

12 companies, largest stake first.

Companies where Rosalind Advisors, Inc. owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
BFRIBiofrontera Inc.13G/A9.90%16.8M shares0.00 ppfrom 9.90%Mar 20, 202411 filingsAug 12, 2026SEC
TLPHTalphera, Inc.13G/A9.90%12.9M shares0.00 ppfrom 9.90%Apr 11, 20255 filingsAug 12, 2026SEC
MYOMyomo, Inc.13G/A9.90%7.40M shares0.00 ppfrom 9.90%May 19, 202115 filingsAug 12, 2026SEC
DCTHDelcath Systems, Inc.13D/A9.90%6.72M shares0.00 ppfrom 9.90%Apr 6, 202114 filingsFeb 10, 2026SEC
PYPDPolyPid Ltd.13G/A9.90%5.12M shares0.00 ppfrom 9.90%Mar 1, 202410 filingsAug 12, 2026SEC
FEMYFemasys Inc13G9.90%4.69M sharesNewAug 14, 20261 filingAug 14, 2026SEC
RGNTRegentis Biomaterials Ltd.13G9.90%1.43M sharesNewAug 13, 20261 filingAug 13, 2026SEC
KPRXKiora Pharmaceuticals Inc13G/A9.90%464.7K shares0.00 ppfrom 9.90%May 29, 20245 filingsFeb 11, 2026SEC
FENCFennec Pharmaceuticals Inc.13G/A9.60%3.32M shares+0.80 ppfrom 8.80%Nov 13, 20254 filingsAug 13, 2026SEC
NSPRInspireMD, Inc.13G/A9.20%11.0M shares−0.70 ppfrom 9.90%Jun 8, 202312 filingsFeb 11, 2026SEC
MDWDMediWound Ltd.13G/A7.00%912.3K shares0.00 ppfrom 7.00%Dec 21, 202210 filingsFeb 11, 2026SEC
CLRBCellectar Biosciences, Inc.13G/A5.50%247.7K shares−4.40 ppfrom 9.90%Jul 8, 202110 filingsFeb 10, 2026SEC

Latest filings

132 filings on file made by Rosalind Advisors, Inc. or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Rosalind Advisors, Inc.
CompanyFiled (ET)FormStakeChangeEvent dateFiling
FEMYFemasys IncAug 14, 202610:49 AM ET13G9.90%4.69M sharesNewAug 10, 2026SEC
RGNTRegentis Biomaterials Ltd.Aug 13, 202611:00 AM ET13G9.90%1.43M sharesNewJun 30, 2026SEC
FENCFennec Pharmaceuticals Inc.Aug 13, 202610:31 AM ET13G/A9.60%3.32M shares+0.80 ppfrom 8.80%Jun 30, 2026SEC
TLPHTalphera, Inc.Aug 12, 20263:04 PM ET13G/A9.90%12.9M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
BFRIBiofrontera Inc.Aug 12, 20262:31 PM ET13G/A9.90%16.8M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
PYPDPolyPid Ltd.Aug 12, 20262:00 PM ET13G/A9.90%5.12M shares0.00 ppfrom 9.90%Jul 31, 2026SEC
MYOMyomo, Inc.Aug 12, 202610:41 AM ET13G/A9.90%7.40M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
FENCFennec Pharmaceuticals Inc.May 14, 20262:50 PM ET13G/A8.80%3.04M shares−1.00 ppfrom 9.80%Mar 31, 2026SEC
TLPHTalphera, Inc.May 12, 20261:22 PM ET13G/A9.90%12.9M shares0.00 ppfrom 9.90%Mar 31, 2025SEC
PYPDPolyPid Ltd.May 12, 202611:24 AM ET13G/A9.90%5.38M shares0.00 ppfrom 9.90%Mar 31, 2026SEC
KPRXKiora Pharmaceuticals IncFeb 11, 20262:00 PM ET13G/A9.90%464.7K shares0.00 ppfrom 9.90%Dec 31, 2025SEC
FENCFennec Pharmaceuticals Inc.Feb 11, 20261:58 PM ET13G/A9.80%2.75M shares+2.30 ppfrom 7.50%Dec 31, 2025SEC
MDWDMediWound Ltd.Feb 11, 202612:59 PM ET13G/A7.00%912.3K shares0.00 ppfrom 7.00%Dec 31, 2025SEC
PYPDPolyPid Ltd.Feb 11, 202612:10 PM ET13G/A9.90%5.48M shares0.00 ppfrom 9.90%Dec 31, 2025SEC
NSPRInspireMD, Inc.Feb 11, 202611:50 AM ET13G/A9.20%11.0M shares−0.70 ppfrom 9.90%Dec 31, 2025SEC
BFRIBiofrontera Inc.Feb 11, 202611:31 AM ET13G/A9.90%16.2M shares0.00 ppfrom 9.90%Dec 31, 2025SEC
TLPHTalphera, Inc.Feb 11, 202610:58 AM ET13G/A9.90%13.2M shares0.00 ppfrom 9.90%Dec 31, 2025SEC
MYOMyomo, Inc.Feb 11, 202610:50 AM ET13G/A9.90%7.60M shares0.00 ppfrom 9.90%Dec 31, 2025SEC
CLRBCellectar Biosciences, Inc.Feb 10, 20263:23 PM ET13G/A5.50%247.7K shares−4.40 ppfrom 9.90%Dec 31, 2025SEC
DCTHDelcath Systems, Inc.Feb 10, 20262:41 PM ET13D/A9.90%6.72M shares0.00 ppfrom 9.90%Dec 31, 2025SEC